PharmaBoardroom

Interview: Peter Coleman – Chief Executive, Cobra…

Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for…

Interview: James Noble – CEO, Adaptimmune, UK

Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in…

Interview: Michael Leek – CEO, TC BioPharm, UK

After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership…

Interview: Hilary Hutton – Squire General Manager UK &…

Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of…

Chris Fox – General Manager, Amgen UK & Ireland

Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role…

Guillermo Castillo – Managing Director, Ipsen Iberia, Spain

The managing director of the Spanish affiliate of one of France’s most exciting and ambitious mid-caps speaks out about crafting a commercial…

Biogen: The Only Hope for Alzheimer’s?

After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field…

Timmo Andersen – General Manager, Boehringer Ingelheim…

Timmo Andersen, general manager of Boehringer Ingelheim in Spain, explains how the affiliate has managed to achieve market-leading growth rates, the…

Novartis Quits Antibiotics Research

In the latest in a wave of Big Pharma companies retreating from the field of antibiotics, Novartis has decided to drop its antibacterial and antiviral…